Skip to content

A Cohort of Patients Undergoing Percutaneous Coronary Intervention

A Longitudinal Cohort of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05719545
Acronym
APCIcohort
Enrollment
10000
Registered
2023-02-09
Start date
2021-12-01
Completion date
2026-12-30
Last updated
2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Myocardial Infarction, Percutaneous Coronary Intervention, Unstable Angina

Brief summary

To investigate the risk factors involved in the occurrence and prognosis of the patients with acute coronary syndrome, patients undergoing percutaneous coronary intervention will be recruited and followed up for at least 2 years.

Detailed description

Patients with acute coronary syndrome undergoing percutaneous coronary intervention will be recruited and prospectively followed up for the incidence of major adverse cardiovascular events (MACE events), including all-cause mortality, cardiovascular mortality, ischemic stroke. Blood and fecal samples will be collected for further analysis. The basic and clinical information will be collected such as diagnosis, medical history, laboratory test results, therapy methods, prognosis and follow-up information. The risk factors involved in the occurrence and prognosis of acute coronary syndrome will be investigated.

Interventions

None listed

Sponsors

Shandong First Medical University
CollaboratorOTHER
Su Guohai
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed as acute coronary syndrome and needed to undergo percutaneous coronary intervention. * \>18 years old.

Exclusion criteria

* With malignant tumors, acute infectious diseases and advanced liver diseases. * Won't sign an inform consent.

Design outcomes

Primary

MeasureTime frameDescription
major adverse cardiovascular events2-year outcome and long-term outcomeall-cause mortality, cardiovascular mortality, ischemic stroke

Countries

China

Contacts

Primary ContactGuohai Su, doctor
huangrong9277@163.com+86-18854125717

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026